Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CFI-400945

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BackgroundCFI-400945 is a first-in-class oral inhibitor of polo-like kinase 4 (PLK4) that regulates centriole duplication… Expand
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2018
2018
Polo-like kinase 4 (PLK4) is a serine/threonine kinase regulating centriole duplication. CFI-400945 is a highly selective PLK4… Expand
Is this relevant?
2018
2018
In “CFI-400945 is not a selective cellular PLK4 inhibitor,” Oegema et al. (1) raise thoughtful comments about our article (2). We… Expand
Is this relevant?
2018
2018
Despite current treatments, lung cancers remain a major public health problem. Innovative ways are needed to treat or prevent… Expand
Is this relevant?
2018
2018
In the PNAS paper “Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers,” Kawakami et al. (1… Expand
Is this relevant?
2017
2017
BACKGROUND Polo-like kinase 4 (PLK4) plays a key role in centriole replication. Hence PLK4 inhibition disrupts mitosis, and… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2016
2016
Background: CFI-400945 is a first-in-class, potent, selective, orally active inhibitor of Polo-like kinase 4 (PLK4) (Ki = 0.26 nM… Expand
Is this relevant?
Review
2015
Review
2015
The identification of novel anticancer agents with high efficacy and low toxicity has always been an intriguing topic in… Expand
Is this relevant?
2015
2015
Previous publications from our laboratory have introduced novel inhibitors of Polo-like kinase 4 (PLK4), a mitotic kinase… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
PLK4 was identified as a promising therapeutic target through a systematic approach that combined RNAi screening with gene… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?